Mass eye‑drop recall announced
What happened
The FDA reported a recall affecting more than 3.1 million eye‑drop products sold through major retailers, creating a large‑scale product‑quality event that can rapidly overwhelm intake and complaint systems. Wide retail distribution increases the risk of fast public attention and regulatory scrutiny over complaint trending and field actions. (thehill.com)
Why it matters
K.C. Pharmaceuticals, a Pomona, California manufacturer, voluntarily initiated the recall on March 3 and the Food and Drug Administration formally classified the event on March 31 as affecting exactly 3,111,072 individual eye‑drop units across eight product types. (healio.com) (thehill.com) The recalled bottles were sold under multiple store‑brand labels and distributed nationwide through large pharmacy and grocery chains including CVS, Walgreens, Rite Aid, Kroger, Walmart, H‑E‑B, Meijer, Harris Teeter and military exchanges; the single largest recalled lot was 1,023,096 bottles sold as “Dry Eye Relief Eye Drops.” (cbsnews.com) (usatoday.com) The agency has recorded this as a Class II action, which the Food and Drug Administration defines as a recall where use of the product may cause temporary or medically reversible adverse health consequences and the probability of serious adverse health consequences is remote. (fda.gov) The stated reason is a “lack of assurance of sterility,” meaning the manufacturer cannot demonstrate that contamination with microbes was prevented during production. (nbcnews.com) Retail tracing information published in news outlets and the FDA enforcement reporting shows affected lot identifiers begin with the prefixes AC, AR, LT, SU, RG, RL, SY or AT, and many recalled bottles carry expiration dates in May 2026 or October 2026; consumers and pharmacies are being advised to check those lot codes and stop using matching products. (geo.tv) (cbsnews.com) K.C. Pharmaceuticals previously received an FDA warning letter after inspections in 2023 that cited objectionable manufacturing conditions, giving regulators a documented inspection history to review as they monitor recall effectiveness and any follow‑on enforcement. (fda.gov) The FDA’s Enforcement Report mechanism is being used to publish classification, lot and UPC details for this event while the agency and the firm coordinate retail removals and consumer notifications. (fda.gov) (nbcnews.com)
Key numbers
- The FDA reported a recall affecting more than 3.1 million eye‑drop products sold through major retailers, creating a large‑scale product‑quality event that can rapidly overwhelm intake and complaint systems.
- Pharmaceuticals, a Pomona, California manufacturer, voluntarily initiated the recall on March 3 and the Food and Drug Administration formally classified the event on March 31 as affecting exactly 3,111,072 individual eye‑drop units across eight product types.
Quick answers
What happened in Mass eye‑drop recall announced?
The FDA reported a recall affecting more than 3.1 million eye‑drop products sold through major retailers, creating a large‑scale product‑quality event that can rapidly overwhelm intake and complaint systems. Wide retail distribution increases the risk of fast public attention and regulatory scrutiny over complaint trending and field actions. (thehill.com)
Why does Mass eye‑drop recall announced matter?
K.C. Pharmaceuticals, a Pomona, California manufacturer, voluntarily initiated the recall on March 3 and the Food and Drug Administration formally classified the event on March 31 as affecting exactly 3,111,072 individual eye‑drop units across eight product types. (healio.com) (thehill.com) The recalled bottles were sold under multiple store‑brand labels and distributed nationwide through large pharmacy and grocery chains including CVS, Walgreens, Rite Aid, Kroger, Walmart, H‑E‑B, Meijer, Harris Teeter and military exchanges; the single largest recalled lot was 1,023,096 bottles sold as “Dry Eye Relief Eye Drops.” (cbsnews.com) (usatoday.com) The agency has recorded this as a Class II action, which the Food and Drug Administration defines as a recall where use of the product may cause temporary or medically reversible adverse health consequences and the probability of serious adverse health consequences is remote. (fda.gov) The stated reason is a “lack of assurance of sterility,” meaning the manufacturer cannot demonstrate that contamination with microbes was prevented during production. (nbcnews.com) Retail tracing information published in news outlets and the FDA enforcement reporting shows affected lot identifiers begin with the prefixes AC, AR, LT, SU, RG, RL, SY or AT, and many recalled bottles carry expiration dates in May 2026 or October 2026; consumers and pharmacies are being advised to check those lot codes and stop using matching products. (geo.tv) (cbsnews.com) K.C. Pharmaceuticals previously received an FDA warning letter after inspections in 2023 that cited objectionable manufacturing conditions, giving regulators a documented inspection history to review as they monitor recall effectiveness and any follow‑on enforcement. (fda.gov) The FDA’s Enforcement Report mechanism is being used to publish classification, lot and UPC details for this event while the agency and the firm coordinate retail removals and consumer notifications. (fda.gov) (nbcnews.com)
